NRXP logo

NRx Pharmaceuticals (NRXP) Company Overview

Profile

Full Name:

NRx Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 4, 2017

Indexes:

Not included

Description:

NRx Pharmaceuticals (NRXP) focuses on developing innovative treatments for central nervous system disorders and other serious conditions. The company aims to address unmet medical needs through advanced research and clinical trials, particularly in areas like depression and neurodegenerative diseases.

Events Calendar

Earnings

Next earnings date:

Apr 1, 2025

Recent quarterly earnings:

Nov 18, 2024

Recent annual earnings:

Apr 1, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 2, 2024

Analyst ratings

Recent major analysts updates

Jan 28, 25 D. Boral Capital
Buy
Jan 6, 25 D. Boral Capital
Buy
Jan 2, 25 D. Boral Capital
Buy
Dec 31, 24 D. Boral Capital
Buy
Dec 2, 24 Ascendiant Capital
Buy
Nov 25, 24 HC Wainwright & Co.
Buy
Nov 15, 24 D. Boral Capital
Buy
Oct 30, 24 EF Hutton
Buy
Oct 21, 24 EF Hutton
Buy
Sep 12, 24 Ascendiant Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for NRx Pharmaceuticals?
  • Does NRx Pharmaceuticals pay dividends?
  • What sector is NRx Pharmaceuticals in?
  • What industry is NRx Pharmaceuticals in?
  • What country is NRx Pharmaceuticals based in?
  • When did NRx Pharmaceuticals go public?
  • Is NRx Pharmaceuticals in the S&P 500?
  • Is NRx Pharmaceuticals in the NASDAQ 100?
  • Is NRx Pharmaceuticals in the Dow Jones?
  • When was NRx Pharmaceuticals's last earnings report?
  • When does NRx Pharmaceuticals report earnings?
  • Should I buy NRx Pharmaceuticals stock now?

What is the ticker symbol for NRx Pharmaceuticals?

The ticker symbol for NRx Pharmaceuticals is NASDAQ:NRXP

Does NRx Pharmaceuticals pay dividends?

No, NRx Pharmaceuticals does not pay dividends

What sector is NRx Pharmaceuticals in?

NRx Pharmaceuticals is in the Healthcare sector

What industry is NRx Pharmaceuticals in?

NRx Pharmaceuticals is in the Biotechnology industry

What country is NRx Pharmaceuticals based in?

NRx Pharmaceuticals is headquartered in United States

When did NRx Pharmaceuticals go public?

NRx Pharmaceuticals's initial public offering (IPO) was on December 4, 2017

Is NRx Pharmaceuticals in the S&P 500?

No, NRx Pharmaceuticals is not included in the S&P 500 index

Is NRx Pharmaceuticals in the NASDAQ 100?

No, NRx Pharmaceuticals is not included in the NASDAQ 100 index

Is NRx Pharmaceuticals in the Dow Jones?

No, NRx Pharmaceuticals is not included in the Dow Jones index

When was NRx Pharmaceuticals's last earnings report?

NRx Pharmaceuticals's most recent earnings report was on Nov 18, 2024

When does NRx Pharmaceuticals report earnings?

The next expected earnings date for NRx Pharmaceuticals is Apr 1, 2025

Should I buy NRx Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions